| 1 |
Alimi Y, Lim WS, Lansbury L, et al. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe [J]. J Clin Virol, 2017, 95(1): 26-35.
|
| 2 |
World Health Organization. World Health Organization (WHO) (2022) Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update [EB/OL].
URL
|
| 3 |
Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections [J]. Sci Transl Med, 2012, 4(165): 165rv13.
|
| 4 |
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients with severe influenza in the intensive care unit: a retrospective cohort study [J]. Lancet Respir Med, 2018, 6(10): 782-792.
|
| 5 |
Waldeck F, Boroli F, Suh N, et al. Influenza-associated aspergillosis in critically ill patients-a retrospective bi-center cohort study [J]. Eur J Clin Microbiol Infect Dis, 2020, 39(10): 1915-1923.
|
| 6 |
Vanderbek L, Spritt I, Brennet C, et al. Invasive pulmonary aspergillosis complicated by severe influenza [J]. Infect the disease, 2018, 31: 471-480.
|
| 7 |
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. A critical influenza care unit for critically ill patients with invasive aspergillosis: a retrospective cohort study [J]. Lancet Resp Med, 2018, 6: 782-792.
|
| 8 |
Schwartz IS, Friedman DZP, Zapernick L, et al. The high incidence of influenza-related invasive pulmonary aspergillosis may not be common: a retrospective cohort study from Alberta, Canada [J]. Clin Infect Dis, 2020, 71: 1760-1763.
|
| 9 |
Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review [J]. J Hosp Infect, 2021 , 113: 115-129.
|
| 10 |
Koehler P, Bassetti M, Chakrabarti A, et al; European Confederation of Medical Mycology; International Society for Human Animal Mycology; Asia Fungal Working Group; INFOCUS LATAM/ISHAM Working Group; ISHAM Pan Africa Mycology Working Group; European Society for Clinical Microbiology; Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology; Association of Medical Microbiology; Infectious Disease Canada.. Definition and treatment of COVID-19-associated pulmonary Aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance [J]. Lancet Infect Dis, 2021, 21(6): e149-e162.
|
| 11 |
Feys S, Gonçalves SM, Khan M, et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study [J]. Lancet Respir Med, 2022, 10(12): 1147-1159.
|
| 12 |
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza:a retrospective cohort study [J]. Lancet Respir Med, 2018, 6: 782-792.
|
| 13 |
Herold S, Becker C, Ridge KM, et al. Influenza virus-induced lung injury: pathogenesis and therapeutic implications [J]. Eur Respir J, 2015, 45(5): 1463-1478.
|
| 14 |
Paul C, Subarao K. Influenza [J]. Lancet, 2017, 390(10095): 697-708.
|
| 15 |
Dewi IM, Janssen NA, Rosati D, et al. Invasive pulmonary aspergillosis associated with viral pneumonitis [J]. Curr Opin Microbiol, 2021, 62: 21-27.
|
| 16 |
Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID-19 [J]. Immunity, 2020, 52(6): 905-909.
|
| 17 |
Espinosa V, Dutta O, McElrath C, et al. Type Ⅲ interferon is a critical regulator of innate antifungal immunity [J]. Sci Immunol, 2017, 2(16): eaan5357.
|
| 18 |
Dutta O, Espinosa V, Wang K, et al. Dectin-1 promotes type Ⅰ and Ⅲ interferon expression to support optimal antifungal immunity in the lung [J]. Front Cell Infect Microbiol, 2020, 10: 321.
|
| 19 |
Kamphuis E, Junt T, Waibler Z, et al. Type Ⅰ interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia [J]. Blood, 2006, 108(10): 3253-3261.
|
| 20 |
Rich HE, McCourt CC, Zheng WQ, et al. Interferon lambda inhibits bacterial uptake during influenza superinfection [J]. Infect Immun, 2019, 87(5): e00114-e00119.
|
| 21 |
Planet PJ, Parker D, Cohen TS, et al. Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection [J]. mBio, 2016, 7(1): e01939-e02015.
|
| 22 |
Ghoneim HE, Thomas PG, McCullers JA. Alveolar macrophage depletion promotes bacterial overinfection during influenza infection [J]. Immune, 2013, 191: 1250-1259.
|
| 23 |
Halstead ES, Chroneos ZC. Deadly flu infections: are macrophages to blame? [J]. Expert Rev Anti Infect Ther, 2015, 13: 1425-1428.
|
| 24 |
Tobin JM, Nickridge KL, Ramanan K, et al. Influenza inhibits neutrophil recruitment to the lungs and exacerbates secondary invasive pulmonary aspergillosis [J]. J Immunol, 2020, 205(2): 480-488.
|
| 25 |
Salazar F, Brown GD. Antifungal innate immunity: perspectives from the past 10 years [J]. J Innate Immun, 2018, 10(5-6): 373-397.
|
| 26 |
Stacey, Schultz-Cherry. The role of NK cells in influenza infection [J]. Microbial Immune, 2015, 386: 109-120.
|
| 27 |
Kramer F, Smith GJD, RamFuchil, et al. Influenza [J]. Nat Rev Dis Primers, 2018, 28, 4(1): 3.
|
| 28 |
Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17 mediated host defense against bacterial pneumonia in mice [J]. J Immunol, 2011, 186(3): 1666-1674.
|
| 29 |
吕雪莲, 刘泽虎, 刘维达. 院内侵袭性曲霉病的环境因素研究进展 [J]. 国际皮肤性病学杂志, 2007, 33(4): 253-255.
|
| 30 |
Verweij PE, Brüggemann RJM, Azoulay E, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis [J]. Intensive Care Med, 2021, 47(8): 819-834.
|
| 31 |
De Pauw B, Walsh TJ, Donnelly JP, et al; EORTC/MSG Consensus Group. Revised definitions of invasive fungal disease from the EORTC/MSG Consensus Group [J]. Clin Infect Dis, 2008, 46(12): 1813-1821.
|
| 32 |
司淑怡. 侵袭性肺曲霉病的诊断进展 [J]. 中国临床医生杂志, 2016, 44(7): 20-23.
|
| 33 |
任增华, 徐玲. 侵袭性肺曲霉病诊断方法的研究进展 [J]. 中医临床医学, 2018, 25(6): 1009-1015.
|
| 34 |
Xu XY, Sun HM, Zhao BL, et al. Bud tree sign in diagnosis of airway invasive pulmonary Aspergillosis in patients with normal immune function: case report and literature review [J]. Mycol Med, 2013, 23(1): 64-69.
|
| 35 |
许娜娜, 周敏, 尹梅, 等. 高通量测序技术在脓毒症病原微生物检测中的价值 [J/OL]. 中华重症医学电子杂志, 2019, 5(2): 10-13.
|
| 36 |
Yin M, Zheng Y, Zhang L, et al. The real-life performance of metagenomic next-generation sequencing in sepsis [J]. J Infect , 2022, 84(3): 418-467.
|
| 37 |
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223): 507-513.
|
| 38 |
Nam H, Ison MG. Aspergillosis complicating severe respiratory syncytial virus (RSV) in ICU patients: a retrospective cohort study [J]. Open Forum Infect Dis, 2020, 7(Suppl. 1): S750.
|
| 39 |
Herbrecht R, Patterson TF, Slavin MA, et al. Application of the 2008 definitions for invasive fungal diseases to the trial compar-ing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group MSG 05and the European Organization for Research and Treatment of Cancer Infectious Diseases Group [J]. Clin Infect Dis, 2015, 60(5): 713-720.
|
| 40 |
Bartoletti M, Pascale R, Cricca M, et al; PREDICO Study Group. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study [J]. Clin Infect Dis, 2021, 73(11): e3606-e3614.
|
| 41 |
Lexander BDA, Perfect JR. Antifungal resistance trends towards the year 2000 [J]. Drugs, 1997, 54(5): 657-678.
|
| 42 |
Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series [J]. Crit Care, 2020, 24(1): 299.
|
| 43 |
Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update from the American Infectious Disease Society [J]. Clin Infect Dis, 2016, 63(4): e1-e60.
|
| 44 |
Ullman AJ, Lipton JH, Viso DH, et al. Posaconazole or fluconazole is used to prevent severe graft host disease [J]. N Engl J Med, 2007, 56(4): 335-47.
|
| 45 |
Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J]. N Engl J Med, 2007, 356(4): 348-359.
|
| 46 |
Sam QH, Yew WS, Seneviratne CJ, et al. Immunomodulation as therapy for fungal infection: are we closer? [J]. Front Microbiol, 2018, 9: 1612.
|
| 47 |
Costantini C, van de Veerdonk FL, Romani L. COVID-19-associated pulmonary aspergillosis: the other side of the coin [J]. Vaccines (Basel), 2020, 8(4): 713.
|
| 48 |
Xi XH, Lu SH, Mu YP. Severe novel influenza A (H1N1) in Shanghai: clinical features, therapeutic management and risk factors for mortality [J]. Infect Int, 2012, 1: 97-102.
|